SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM is trending as its board rejected an "undervalued" CEO buyout offer and confirmed it's now evaluating multiple competitive acquisition proposals from major shipping players like Hapag-Lloyd and MSC. The community is buzzing with buyout speculation, anticipating a bidding war to unlock ZIM's substantial intrinsic value and cash reserves amidst rising container rates, despite Israeli regulatory and union concerns.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

WEEDCOIN CRYPTO is trending as its community rallies around building a global cannabis culture on Solana and anticipating a run-up into the upcoming 4/20, leveraging broader discussions around cannabis legalization. While supporters emphasize its long-term cultural vision, skeptics continue to label it as a volatile meme coin.

iShares Trust - iShares 0-3 Month Treasury Bond ETF

iShares 0-3 Month Treasury Bond ETF

SGOV is trending as investors increasingly flock to its safety and appealing 4-5% monthly dividend yield, actively parking cash amidst elevated market uncertainty and high equity valuations while anticipating future buying opportunities in broader indices.

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals plc

Jazz Pharmaceuticals is surging after announcing strong Phase 3 clinical trial results for its cancer drug Ziihera in gastroesophageal cancer and receiving FDA accelerated approval for Ziihera in biliary tract cancer. This success has ignited investor confidence, fueling analyst upgrades and widespread community discussion about the drug's potential to establish a new standard of care in oncology.

Featured in Matt Furies latest book Cortex Vortex as Ratos nemesis. The character is also part of ZOGZ which confirms its real name.  Matt Furie, the artist best known for creating Pepe the Frog, has been working on a new book. The news comes from his editor, who goes by the handle @beuys_on_sale_ on Instagram. In a recent post, the editor hinted at an upcoming project featuring new characters named Gasspas and Rato. Gasspas’s visual appearance can be inferred from the artwork. In one illustration, Gasspas is depicted looming over two rats (Rato and Wat), gazing down at them in a menacing way (an image that has circulated among collectors). This inferred that Gasspas is Ratos nemesis in the new book Cortex Vortex reinforced by community quips that “cats eat rats”. Gasspas debuted as part of ZOGZ, a collection of 111 original NFT character illustrations by Matt Furie launched in May 2023.

Gasspas

Gasspas ($GASS) is trending as the community speculates on its potential to be "the next PEPE," fueled by comparisons and discussions of alleged backing from PEPE creator Matt Furie. This narrative drives calls to buy and hold, even as some community members label it a pump and dump amidst volatile price action.

Bridgford Foods Corp. engages in the manufacture, market, and distribution of frozen and snack food products. It operates through the Frozen Food Products and Snack Food Products segments. The Frozen Food Products segment manufactures and distributes food products, including biscuits, bread dough items, roll dough items, and sandwiches. The Snack Food Products segment distributes both products manufactured by the company and third parties. The company was founded by Hugh H. Bridgford in February 1932 and is headquartered in Dallas, TX.

Bridgford Foods Corp.

Bridgford Foods Corporation

Bridgford Foods (BRID) is garnering significant attention as the community anticipates dramatically improved gross profit margins, driven by President Trump's initiative to increase beef imports, which is expected to considerably lower input costs. This potential catalyst, alongside accelerating private-label sales with major retailers, is fueling discussions about unlocking the microcap's deeply undervalued assets and inspiring speculation of a potential take-private transaction, further supported by consistent insider buying.

Canadian Solar, Inc. engages in the manufacture of solar photovoltaic modules, provision of solar energy and battery storage solutions, and development of utility-scale solar and battery storage products. It operates through the CSI Solar and Global Energy segments. The CSI Solar segment designs, develops, and manufactures solar ingots, wafers, cells, modules, and other solar power and battery storage products. The Global Energy segment includes solar and battery storage project development and sale, asset management services for operational projects, sale of electricity, and investment in retained assets. The company was founded by Shawn Qu in October 2001 and is headquartered in Kitchener, Canada.

Canadian Solar Inc

Canadian Solar (CSIQ) is trending due to widespread community allegations of market manipulation and a recent convertible notes offering, which many shareholders perceive as detrimental, fueling frustration over its valuation despite strategic moves in US manufacturing and IRA tax credit potential.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPE CRYPTO is trending amidst significant price volatility, prompting community discussion on whether its recent upward movement is sustainable or a typical "pump and dump" pattern. As participants actively debate buying the dips versus shorting, the broader memecoin market is seeing renewed interest with talk of a potential "meme season."

J.P. Morgan Exchange-Traded Fund Trust - JPMorgan Equity Premium Income ETF

JPMorgan Equity Premium Income ETF

JPMorgan Equity Premium Income ETF ($JEPI) is actively discussed as investors prioritize consistent monthly income amidst market volatility, with many highlighting its defensive qualities and resilience during market dips. The community is debating its role in income-focused portfolios, often comparing its stability and dividend tax treatment against other high-yield covered call ETFs.

Qualys, Inc. engages in the provision of cloud security and compliance solutions. Its products enable organizations to identify security risks to information technology infrastructures, help protect information technology systems and applications from cyber attacks, and achieve compliance with internal policies and external regulations. The firm also offers solutions through a software-as-a-service model, primarily with renewable annual subscriptions. The company was founded on December 30, 1999 and is headquartered in Foster City, CA.

Qualys Inc

Qualys Inc. is trending after its latest earnings report, which, despite beating quarterly expectations, led to a sharp stock drop due to a disappointing full-year revenue growth outlook. The community is actively debating if this significant dip presents a buying opportunity, particularly amid broader discussions about cybersecurity infrastructure's resilience against "AI replacement" concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Beacon Harbor Wealth Advisors Inc. Makes New $4.31 Million Investment in Rigel Pharmaceuticals, Inc. $RIGL

Beacon Harbor Wealth Advisors Inc. purchased a new stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing...

Rigel Appoints Michael P. Miller to the Board of Directors

Rigel Appoints Michael P. Miller to the Board of Directors Rigel Appoints Michael P. Miller to the Board of Directors PR Newswire SOUTH SAN FRANCISCO, Calif., Feb. 3, 2026 SOUTH SAN FRANCISCO...

FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside?

Amicus and Rigel target rare diseases, but a pending BioMarin buyout and growing drug sales set up different upside paths for investors.

Rigel Pharmaceuticals (NASDAQ:RIGL) Downgraded to "Strong Sell" Rating by Zacks Research

Zacks Research lowered shares of Rigel Pharmaceuticals from a "strong-buy" rating to a "strong sell" rating in a report on Tuesday...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Sees Significant Growth in Short Interest

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totaling 3,439,339 shares...

Profound Medical (PROF) Soars 9.5%: Is Further Upside Left in the Stock?

Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

HC Wainwright Has Negative Forecast for RIGL FY2026 Earnings

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) - Analysts at HC Wainwright lowered their FY2026 earnings per share estimates for Rigel Pharmaceuticals in a research report issued to clients...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the seven research firms that are currently covering the stock...

Rigel Provides Business Update and 2026 Outlook

Rigel Provides Business Update and 2026 Outlook Rigel Provides Business Update and 2026 Outlook PR Newswire SOUTH SAN FRANCISCO, Calif., Jan. 12, 2026 Preliminary fourth quarter 2025 total revenue of...

CNC Deepens Medicaid Strategy With Cityblock Partnership in Illinois

Centene expands its Medicaid strategy by partnering with Cityblock Health to serve 10,000 Illinois members with 24/7 wrap-around care.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

Stocktwits

Stocktwits Polls

Users question management's transparency and credibility, with some wondering about their approach to new growth opportunities and shareholder communication.

Current Price	$34.32
Prev Close	$34.22
Open	$34.22
Dividend Yield	0.00%
50-Day Moving Average	$39.90
Beta	1.33
Avg. Volume	434,305.95
PE Ratio	5.57

52-Week High	$52.24
52-Week Low	$15.50
Market Capitalization	$622.95M
EPS (Annual)	$0.9886
Price to Book	5.29
Revenue Per Employee	$1.09M

RIGL
Rigel Pharmaceuticals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RIGL News

RIGLRigel Pharmaceuticals